Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centanafadine long-term safety in adult ADHD
NCT03605849Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Feb 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of centanafadine in attention deficit hyperactivity disorder (ADHD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Treatment-emergent Adverse Events at 56 weeks. Started Feb 2019; status: completed.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03605849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03605849.